Medicure Inc. (OTCMKTS:MCUJF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday. The brokerage presently has a $7.00 price objective on the stock. Zacks Investment Research‘s target price indicates a potential upside of 12.18% from the stock’s previous close.
According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “
Separately, ValuEngine raised shares of Medicure from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th.
Medicure (OTCMKTS:MCUJF) opened at 6.24 on Thursday. The firm’s 50-day moving average is $6.41 and its 200-day moving average is $6.38. Medicure has a 52 week low of $4.11 and a 52 week high of $7.96. The company has a market cap of $97.13 million, a PE ratio of 6.14 and a beta of 0.59.
TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/12/medicure-inc-otcmktsmcujf-stock-rating-upgraded-by-zacks-investment-research.html.
Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Medicure Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Medicure Inc. and related companies.